Lobomycosis is a chronic granulomatous fungal infection of the skin and subcutaneous tissues characterized by nodular or keloid-like lesions, first described by Jorge Lobo in 1930.1
It is caused by Lacazia loboi, an uncultivable fungus classified in the group of the Onygenales order and Ajellomycetaceae family.2 Lacazia loboi is saprophytic in soil, vegetation, and water in hot and humid forest areas with large rivers. Patients, usually rural workers and fishermen, are infected through the inoculation of the fungus into the dermis after a trauma or an insect bite. Lobomycosis is also considered an emerging zoonotic mycosis as it can also occur after direct and indirect human contact with dolphins, in particular, the bottlenose dolphin, the only animals known so far to be naturally infected.3
Lobomycosis is endemic in rural areas of the Amazon basin (Brazil, Ecuador, Venezuela, Guyana, Suriname, Bolivia, Peru, and Colombia), as well as in French Guiana, Panama, Costa Rica, and Mexico where it affects indigenous people and dolphins.3 To date, about 500 human cases have been reported worldwide, 318 of them in Brazil.3,4 The occurrence of lobomycosis outside Central and South America is exceedingly rare, although autochthonous cases have been reported in Africa and Greece.5,6
Here we report a case acquired in the Amazon Region of Venezuela, 17 years earlier. The patient gave his informed consent.
Taborda PR, Taborda VA, McGinnis MR, 1999. Lacazia loboi gen. nov., comb. nov., the etiologic agent of lobomycosis. J Clin Microbiol 37: 2031–2033.
Herr RA, Tarcha EJ, Taborda PR, Taylor JW, Ajello L, Mendoza L, 2001. Phylogenetic analysis of Lacazia loboi places this previously uncharacterized pathogen within the dimorphic Onygenales. J Clin Microbiol 39: 309–314.
Paniz-Mondolfi A, Talhari C, Sander Hoffmann L, Connor DL, Talhari S, Bermudez-Villapol L, Hernandez-Perez M, Van Bressem MF, 2012. Lobomycosis: an emerging disease in humans and delphinidae. Mycoses 55: 298–309.
Woods WJ, Belone Ade F, Carneiro LB, Rosa PS, 2010. Ten years experience with Jorge Lobo’s disease in the state of Acre, Amazon region, Brazil. Rev Inst Med Trop Sao Paulo 52: 273–278.
Papadavid E, Dalamaga M, Kapniari I, Pantelidaki E, Papageorgiou S, Pappa V, Tsirigotis P, Dervenoulas I, Stavrianeas N, Rigopoulos D, 2012. Lobomycosis: a case from southeastern Europe and review of the literature. J Dermatol Case Rep 6: 65–69.
Bhawan J, Bain RW, Purtilo DT, Gomez N, Dewan C, Whelan CF, Dolorum SM, Edelstein L, 1976. Lobomycosis. An electron microscopic, histochemical and immunologic study. J Cutan Pathol 3: 5–16.
Saint-Blancard P, Maccari F, Le Guyadec T, Lanternier G, Le Vagueresse R, 2000. Lobomycosis: a mycosis seldom observed in metropolitan France. Ann Pathol 20: 241–244.
Burns RA, Roy JS, Woods C, Padhye AA, Warnock DW, 2000. Report of the first human case of lobomycosis in the United States. J Clin Microbiol 38: 1283–1285.
Fischer M, Chrusciak Talhari A, Reinel D, Talhari S, 2002. Sucessful treatment with clofazimine and itraconazole in a 46 year old patient after 32 years duration of disease. Hautarzt 53: 677–681.
Arju R, Kothadia JP, Kaminski M, Abraham S, Giashuddin S, 2014. Jorge Lobo’s disease: a case of keloidal blastomycosis (lobomycosis) in a nonendemic area. Ther Adv Infect Dis 2: 91–96.
White TJ, Bruns T, Lee S, Taylor J, 1990. Amplification and Direct Sequencing of Fungal Ribosomal RNA Genes for Phylogenetics. San Diego, CA: Academic Press.
Francesconi VA, Klein AP, Santos AP, Ramasawmy R, Francesconi F, 2014. Lobomycosis: epidemiology, clinical presentation, and management options. Ther Clin Risk Manag 10: 851–860.
Carrasco-Zuber JE, Navarrete-Dechent C, Bonifaz A, Fich F, Vial-Letelier V, Berroeta-Mauriziano D, 2016. Cutaneous involvement in the deep mycoses: a review. Part II—Systemic mycoses. Actas Dermosifiliogr 107: 816–822.
Queiroz-Telles F, Nucci M, Colombo AL, Tobon A, Restrepo A, 2011. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment. Med Mycol 49: 225–236.